



## Chimeric Antigen Receptors against Cancers and Autoimmune Diseases

Guest Editor:

**Prof. Dr. Niels Schaft**

Department of Dermatology,  
Universitätsklinikum Erlangen,  
91054 Erlangen, Germany

Deadline for manuscript  
submissions:

**31 December 2024**

### Message from the Guest Editor

Dear Colleagues,

The development of chimeric antigen receptors (CARs) has marked a new era in cancer immunotherapy. Tremendous clinical advances have been achieved via the use of CAR-T cells against a variety of cancers both in preclinical studies and in clinical trials, most notably against leukemia, lymphoma, and multiple myeloma; these studies have resulted in the FDA and EMA approval of these CAR-T-cell therapies. Nevertheless, approximately 50% of patients treated with these approved CAR products experience relapse or refractory disease that necessitates salvage strategies. Furthermore, in patients with solid tumors, CAR-T-cell infusions have not yet been able to induce complete and durable remission. Very recently, the clinical efficacy of CAR-T cells was also proven in patients with autoimmune diseases.

Due to the rapid evolution of this field, the aim of this Special Issue is to focus on advancements and novel strategies regarding CARs for the therapy of cancer and autoimmune diseases.

Prof. Dr. Niels Schaft  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Maurizio Battino

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

## Contact Us

---

*International Journal of Molecular  
Sciences* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/ijms  
ijms@mdpi.com  
X@IJMS\_MDPI